

25th April, 2018

In response to your request for an update on access to SPINRAZA (nusinersen) in Europe, please see the table below.

Access to reimbursed treatment

In Europe and across the region, since the last update in March, significant progress has been made in Switzerland, Finland and Slovenia. For full details, please see the following table:

Access & Reimbursement Details By Country	
Austria	Reimbursed access - Types I, II and III
Belgium	Negotiations underway
Bulgaria	Partner in place; preparing for reimbursement dossier submission
Croatia	Preparing for reimbursement dossier submission; current access is through a named patient programme; negotiations for national reimbursement underway
Cyprus	Pricing submission is being evaluated by authorities
Czech Republic	Negotiations underway ; currently limited access is through a named patient programme
Denmark	Negotiations ongoing; reimbursed access restricted to presymptomatic & Type 1
England & Wales	Access & Reimbursement dossier submitted March 2018
Estonia	Partner in place; preparing for reimbursement dossier submission
Finland	Reimbursed access for patients up to, and including, 17 years old, aligned with PALKO positive recommendation.
France	Negotiations underway; current reimbursed access given to Types I, II and III through post ATU
Germany	Negotiations underway; reimbursed access given to Types I, II and III
Greece	Reimbursed access for Types I and II; negotiations for Type III underway
Hungary	Biogen & NEAK agreement signed. Final access decisions will be made by NEAK as per the Rare Disease Committee criteria in response to all individual applications.
Iceland	Partner in place; preparing for reimbursement dossier submission
Ireland	Negotiations underway
Israel	Reimbursed access - Types I, II and III
Italy	Reimbursed access - Types I, II and III
Kuwait	Negotiations underway; current access through a named patient programme
Latvia	Partner in place; preparing for reimbursement dossier submission
Lithuania	Partner in place; negotiations underway for individual reimbursement; preparing for reimbursement dossier submission
Luxembourg	Reimbursed access - Types I, II and III

Macedonia	Negotiations underway
Netherlands	Negotiations underway
Northern Ireland	Negotiations underway
Norway	Reimbursed access -Types I, II and III (0 to 18 years of age)
Poland	Positive recommendation for broad patient population by President of Transparency Commission - negotiations underway
Portugal	Negotiations underway
Qatar	Negotiations underway; current access through a named patient programme
Romania	Positive HTA report published; negotiations to begin soon
Russia	Partner in place; preparing for reimbursement dossier submission
Saudi Arabia	Negotiations underway; current access through a named patient programme
Scotland	Negotiations underway
Serbia	Negotiations underway; currently patients do not have access in any form
Slovakia	Negotiations underway
Slovenia	Reimbursed access Types I, II and III pediatric patients as of March 30, 2018
Spain	Reimbursed access agreed - Types I, II and III
Sweden	Reimbursed access – Pediatric (initiated below 18 years old) Types I, II and IIIa
Switzerland	Reimbursed access (pre-symptomatic and Type I, II, III) up to 20 years old; Individual reimbursement for patients above 20
Turkey	Negotiations ongoing; current access through a named patient programme
Ukraine	Partner in place; preparing for reimbursement dossier submission
UAE	Negotiations underway; current access through a named patient programme

We remain a dedicated committed partner to this community and will continue to be available to provide updates in the future, when requested.

Best regards,

The Biogen SMA Team